In its latest 10-Q filed May 15, 2026, AIM ImmunoTech reported ongoing non-compliance with NYSE American stockholders' equity requirements, holding a plan to restore compliance by June 11, 2026. The company continues clinical development of Ampligen, focusing on pancreatic cancer in combination with AstraZeneca’s Imfinzi, supported by broad patent protection and orphan drug exclusivities. However, dependency on outsourced manufacturing and limited commercial revenues underscore operational risks. Capital raising through rights offerings and ATM sales agreements remains critical for sustaining R&D programs and exchange listing. The niche therapeutic target in pancreatic cancer offers potential upside if clinical data validates the drug candidate’s efficacy.